OmniSeq

OmniSeq Overview

Founded 2015
Founded
Status Private
Employees 50
Employees
Latest Deal Type Angel
Latest Deal Amount $1.57M
Latest Deal Amount
Investors 2

OmniSeq General Information

Description

Developer of molecular therapy technologies designed to improve access and better cancer treatment options through comprehensive molecular profiling. The company's molecular therapy technologies consist of a platform known as OmniSeq Target which is a differentiated cancer diagnostic that leverages dual next-generation sequencing (dual NGS) and a proprietary algorithm that resolves inconsistencies in solid tumor identification, yielding highly accurate results with essentially no false positives and focuses on precision, connectivity and collaboration, enabling cancer patients to get treatment through advanced and accurate therapeutic technologies.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Therapeutic Devices
Outcome Management (Healthcare)
Primary Office
  • 700 Ellicott Street
  • Buffalo, NY 14203
  • United States
+1 (800) 000-0000

OmniSeq Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OmniSeq Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 20-Jun-2019 $1.57M 000.00 Completed Startup
2. Corporate (Series B) 02-May-2019 000.00 000.00 Completed Generating Revenue
1. Corporate 17-Jun-2015 $20M $20M Completed Generating Revenue

OmniSeq Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Agendia Private Equity-Backed Irvine, CA 000 00000 0000000 0000 00000
00000000 Venture Capital-Backed Toronto, Canada 00 0000 0000000000 0
0000000 0000 Venture Capital-Backed Sunnyvale, CA 00 0000 000000 00 0000
00000000000 Venture Capital-Backed Dania Beach, FL 00 00000 0000000000 0 00000
00000000 Venture Capital-Backed Austin, TX 000 000.00 00000000000 000.00

OmniSeq Executive Team (6)

Name Title Board Seat Contact Info
Mark Gardner Chief Executive Officer & Board Member
Candace Johnson Ph.D Chief Executive Officer
Carl Morrison MD President, Chief Scientific Officer, Founder and Board Member
Margot Schoenborn JD Chief Administrative Officer, General Counsel, Compliance and Privacy Officer & Corporate Secretary
Matt Klusas Chief Commercial Officer

OmniSeq Board Members (5)

Name Representing Role Since
Buford Sears OmniSeq Board Member 000 0000
Kenneth Manning OmniSeq Board Member 000 0000
Mark Gardner OmniSeq Chief Executive Officer & Board Member 000 0000
Paul Billings Ph.D OmniSeq Board Member 000 0000
Ronnie Andrews OmniSeq Board Member 000 0000

OmniSeq Investors (2)

To view OmniSeq‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Laboratory Corporation of America Corporation Minority 000 0000 000000 0
Roswell Park Cancer Institute Corporation Minority 000 0000 000000 0

Ready to get started?

Request a free trial